HB 1252 - Controlled substances; amend listing; remove cert penalty

First Reader Summary

A BILL to amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled substances, so as to change the listing of controlled substances and dangerous drugs; to delete certain penalty provisions relating to carisoprodol; and for other purposes.

Page Numbers - 1/ 2/ 3/ 4/ 5

HB 1252                                            HB 1252/AP 
 
      H. B. No. 1252 (AS PASSED HOUSE AND SENATE) 
      By:  Representatives Parham of the 122nd, Twiggs of the 8th, 
      Martin of the 145th, Parrish of the 144th, Stephens of the 
      150th and others 
 
                        A BILL TO BE ENTITLED 
                               AN ACT 
 
 
  1- 1  To amend Chapter 13 of Title 16 of the Official Code of 
  1- 2  Georgia Annotated, relating to controlled substances, so as 
  1- 3  to change the listing of controlled substances and dangerous 
  1- 4  drugs; to delete certain penalty provisions relating to 
  1- 5  carisoprodol; to provide an effective date; to repeal 
  1- 6  conflicting laws; and for other purposes. 
 
  1- 7       BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA: 
 
  1- 8                           SECTION 1. 
 
  1- 9  Chapter 13 of Title 16 of the Official Code of Georgia 
  1-10  Annotated, relating to controlled substances, is amended by 
  1-11  striking the period and inserting a semicolon at the end of 
  1-12  subparagraph (AA) of paragraph (6) of Code Section 16-13-27, 
  1-13  relating to Schedule III controlled substances, and 
  1-14  inserting immediately thereafter the following: 
 
  1-15      "(7) Ketamine." 
 
  1-16                           SECTION 2. 
 
  1-17  Said chapter is further amended by adding in the appropriate 
  1-18  position in subsection (a) of Code Section 16-13-28, 
  1-19  relating to Schedule IV controlled substances, the 
  1-20  following: 
 
  1-21      "(30.15) Sibutramine;". 
 
  1-22                           SECTION 3. 
 
  1-23  Said chapter is further amended by striking from subsection 
  1-24  (b) of Code Section 16-13-71, listing the dangerous drugs, 
  1-25  the following paragraphs: 
 
  1-26      (12.1) Reserved; 
 
  1-27      (258) Dexbrompheniramine; 
 
  1-28      (399) Reserved; 
 
  1-29      (411.5) Ganciclovir sodium; 
 
  1-30      (508) Ketamine; 
 
 
                                 -1- 
 
 
 
  2- 1      (509.1) Ketoconazole;". 
 
  2- 2                           SECTION 4. 
 
  2- 3  Said chapter is further amended by adding in the appropriate 
  2- 4  positions in subsection (b) of Code Section 16-13-71, 
  2- 5  listing the dangerous drugs, the following paragraphs: 
 
  2- 6      "(3.5) Acetic acid, glacial; 
 
  2- 7      (12.1) Acitretin; 
 
  2- 8      (44.3) Amlexanox; 
 
  2- 9      (50.3) Anagrelide; 
 
  2-10      (62.7) Ardeparin; 
 
  2-11      (68.13) Atorvastatin; 
 
  2-12      (72.4) Azelastine; 
 
  2-13      (83.5) Bentoquatam--See exceptions; 
 
  2-14      (94.5) Betaine, anhydrous; 
 
  2-15      (107.5) Brimonidine; 
 
  2-16      (116.05) Buprenorphine; 
 
  2-17      (119.05) Butenafine; 
 
  2-18      (122.5) Cabergoline; 
 
  2-19      (159.8) Cerivastatin; 
 
  2-20      (236.6) Daclizumab; 
 
  2-21      (237.7) Danaparoid; 
 
  2-22      (244.5) Delavirdine; 
 
  2-23      (258)  Dexbrompheniramine--See exceptions; 
 
  2-24      (316.5) Donepezil; 
 
  2-25      (379.07) Etomidate; 
 
  2-26      (383.3) Ferumoxides; 
 
  2-27      (383.4) Ferumoxsil; 
 
  2-28      (399)  Fluoxetine; 
 
  2-29      (406.5) Fosfomycin; 
 
  2-30      (406.9) Fosphenytoin; 
 
  2-31      (411.5) Ganciclovir; 
 
 
 
                                 -2- 
 
 
 
  3- 1      (415.03) Glatiramer; 
 
  3- 2      (446.6) Hyaluronan; 
 
  3- 3      (446.7) Hyaluronic acid; 
 
  3- 4      (466.5) Imiquimod; 
 
  3- 5      (506.8) Ivermectin; 
 
  3- 6      (508)  Reserved; 
 
  3- 7      (509.1) Ketoconazole--See exceptions; 
 
  3- 8      (517.2) Levofloxacin; 
 
  3- 9      (546.5) Meclocycline; 
 
  3-10      (615.6) Mibefradil; 
 
  3-11      (617.1) Midodrine; 
 
  3-12      (617.4) Miglitol; 
 
  3-13      (638.8) Nelfinavir; 
 
  3-14      (644.4) Nilutamide; 
 
  3-15      (661.8) Olanzapine; 
 
  3-16      (663.2) Olopatadine; 
 
  3-17      (692.8) Penciclovir; 
 
  3-18      (703.03) Pentosan; 
 
  3-19      (727.2) Phenytoin; 
 
  3-20      (743.3) Podofilox; 
 
  3-21      (831.02) Raloxifene; 
 
  3-22      (845.5) Ropivacaine; 
 
  3-23      (851.03) Samarium SM 153 lexidronam; 
 
  3-24      (883.8) Sparfloxacin; 
 
  3-25      (931.1) Tamsulosin; 
 
  3-26      (931.3) Tazarotene; 
 
  3-27      (966.6) Tiludronate; 
 
  3-28      (967.7) Tizanidine; 
 
  3-29      (973.1) Topiramate; 
 
  3-30      (973.4) Toremifene; 
 
  3-31      (973.9) Tranexamic acid; 
 
 
                                 -3- 
 
 
 
  4- 1      (1003.5) Troglitazone; 
 
  4- 2      (1024.5) Valsartan; 
 
  4- 3      (1042.01) Zafirlukast; 
 
  4- 4      (1042.4) Zileuton; 
 
  4- 5      (1042.7) Zinc acetate--see exceptions;". 
 
  4- 6                           SECTION 5. 
 
  4- 7  Said chapter is further amended by striking from subsection 
  4- 8  (c) of Code Section 16-13-71, listing the dangerous drugs, 
  4- 9  the following: 
 
  4-10      "(14.2) Minoxidil--when used with a strength up to 2 
  4-11      percent in a topical skin product; 
 
  4-12      (23) Pseudoephedrine--where the dosage unit is not more 
  4-13      than 60 mg. or, when manufactured to release the drug in 
  4-14      delayed action slow time release, where the dosage unit 
  4-15      is not more than 120 mg.; 
 
  4-16      (27.5) Tioconazole--when used with a strength up to 1 
  4-17      percent in a topical product;". 
 
  4-18                           SECTION 6. 
 
  4-19  Said chapter is further amended by adding in the appropriate 
  4-20  positions in subsection (c) of Code Section 16-13-71, 
  4-21  listing the dangerous drugs, the following: 
 
  4-22      (3.5) Bentoquatam--when used with a strength of 5 
  4-23      percent or less in topical preparations; 
 
  4-24      (7.9) Dexbrompheniramine--when a single dosage unit is 6 
  4-25      mg. or less; 
 
  4-26      (12.3) Ketoconazole--when used with a strength of 1 
  4-27      percent or less in topical preparations; 
 
  4-28      (14.2) Minoxidil--when used with a strength of 5 percent 
  4-29      or less in topical preparations; 
 
  4-30      (23) Pseudoephedrine--when a single dosage unit is 60 
  4-31      mg. or less or when manufactured in an extended release 
  4-32      form with a dosage unit of 240 mg. or less; 
 
  4-33      (27.5) Tioconazole--when used with a strength of 1 
  4-34      percent or less in topical preparations or when used 
  4-35      with a strength of 6.5 percent or less in vaginal 
  4-36      preparations; 
 
 
 
 
                                 -4- 
 
 
 
  5- 1      (29.5) Zinc acetate--when used in topical 
  5- 2      preparations;". 
 
  5- 3                           SECTION 7. 
 
  5- 4  Said chapter is further amended by striking subsection (d) 
  5- 5  of Code Section 16-13-79, relating to penalties, which reads 
  5- 6  as follows: 
 
  5- 7    "(d) Any person who obtains carisoprodol by fraud, theft, 
  5- 8    deceit, misrepresentation, subterfuge, forgery or 
  5- 9    alteration of a prescription or written order, concealment 
  5-10    of a material fact, or the use of a false name shall be 
  5-11    guilty of a felony and punished by imprisonment for not 
  5-12    less than one year nor more than three years or by a fine 
  5-13    not to exceed $5,000.00 or both." 
 
  5-14                           SECTION 8. 
 
  5-15  This Act shall become effective upon its approval by the 
  5-16  Governor or upon its becoming law without such approval. 
 
  5-17                           SECTION 9. 
 
  5-18  All laws and parts of laws in conflict with this Act are 
  5-19  repealed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                 -5-